Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly revealed major advancements in its alopecia and atopic dermatitis studies, likely driving its 3.77% stock rise. The ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...

We recently published a list of Jim Cramer Discusses These 13 Stocks & Criticizes Billionaires. In this article, we are going ...

Eli Lilly is offering vials of its obesity drug Zepbound to patients at a discount — but only if they skip their insurance.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

People who get moderate to vigorous physical activity may be less likely to develop dementia, stroke, anxiety, depression, and sleep disorders, according to a preliminary study released February 27, ...

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announced today a poster presentation at SECO 2025 being held from February 26 ? March 2 in Atlanta, Georgia. Mile Brujic, OD, FAAO of Premier ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical ...